Gilead buys Arcellx for $7.8B to bolster CAR-T push against Carvykti
TL;DR Summary
Gilead agreed to acquire Arcellx for about $7.8 billion in cash to take full control of the BCMA-targeted CAR-T therapy anito-cel as FDA review proceeds, paying $115 a share—a 68% premium to Arcellx's 30-day VWAP with a $5-per-share contingent payout if global sales reach $6 billion by 2029; the deal aims to sharpen Gilead's cell-therapy portfolio and compete with J&J/Legend's Carvykti, with analysts noting anito-cel's safety profile and potential to restore momentum for Gilead's Kite unit.
- Gilead inks $8B Arcellx buyout to steer CAR-T into J&J showdown Fierce Biotech
- Here's Why Shares of Arcellx Are Up Almost 80% Today Yahoo Finance
- Gilead to buy cancer therapy developer Arcellx for up to $7.8 billion CNBC
- Gilead Sciences to Buy Arcellx in Deal Valued at $7.8 Billion WSJ
- Gilead Bets Big On New Drug With $7.8 Billion Deal As It Takes On J&J Investor's Business Daily
Reading Insights
Total Reads
1
Unique Readers
3
Time Saved
2 min
vs 3 min read
Condensed
82%
422 → 76 words
Want the full story? Read the original article
Read on Fierce Biotech